research News

Philadelphia, PA – Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, representing more than 30% of all pediatric cases. A pilot study in The Journal of Molecular Diagnostics, published by Elsevier, confirms the feasibility of implementing an RNA sequencing analysis (RNA-Seq) workflow for clinical diagnosis of molecular subtypes...
MEMPHIS, Tenn. – Scientists at St. Jude Children’s Research Hospital described the gene regulatory networks contributing to differences between subtypes of the most common childhood cancer, acute lymphoblastic leukemia (ALL). The work examined chromatin, the packaging that compacts DNA, in a cohort of patient samples six times greater than any...
Basel, Switzerland – After a lackluster data leak in 2023, Roche’s Genentech is turning the tables with positive Phase III data for its anti-TIGIT immunotherapy. The subsidiary revealed study results Tuesday in an abstract at this week’s American Society of Clinical Oncology Gastrointestinal Cancers Symposium. In patients with esophageal squamous...
Catonsville, Maryland – Prostate cancer is the most common cancer in men other than skin cancer, and more than 288,000 new cases are diagnosed every year, according to the American Cancer Society. The disease’s fatality rate has decreased by more than half since the 1990s, but there is still room...
Cambridge, UK – Large-scale genetic analysis has helped researchers uncover the interplay between cancer-driving genetic mutations and inherited genetic variants in a rare type of blood cancer. Researchers from the Wellcome Sanger Institute, the University of Cambridge, and collaborators, combined various comprehensive data sets to understand the impact of both...
Paris, France – With ECRD 2024 scheduled for 15 and 16 May in Brussels and online, EURORDIS’ session, Revolutionising Funding Strategies for Breakthrough Therapies in Rarer Diseases, will address this critical issue. This session will not only highlight best practices but also showcase examples of therapies developed through innovative funding...
CAMBRIDGE, Mass. & LEICESTER, England — RS Oncology (RSO), a clinical stage biotechnology company developing innovative therapies to eradicate mesothelioma and other diseases, today announced the successful dosing of the first patient in the Phase 2 dose expansion portion of its United Kingdom multicenter study (MITOPE; NCT05278975). Malignant pleural effusion...
New Brunswick, NJ – Women with HIV experience accelerated DNA aging, a phenomenon that can lead to poor physical function, according to a study led by Stephanie Shiau, an assistant professor in the Department of Biostatistics and Epidemiology at the Rutgers School of Public Health. Published in The Journal of...